Zacks Research Has Positive Outlook of BIO FY2026 Earnings

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Stock analysts at Zacks Research boosted their FY2026 earnings per share estimates for Bio-Rad Laboratories in a note issued to investors on Tuesday, August 25th. Zacks Research analyst Team now expects that the medical research company will earn $9.71 per share for the year, up from their previous estimate of $9.42. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $9.14 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q2 2027 earnings at $2.23 EPS, Q3 2027 earnings at $2.25 EPS, Q4 2027 earnings at $2.32 EPS, FY2027 earnings at $9.02 EPS, Q2 2028 earnings at $2.32 EPS and FY2028 earnings at $9.26 EPS.

BIO has been the subject of a number of other research reports. Citigroup lifted their target price on shares of Bio-Rad Laboratories from $300.00 to $330.00 and gave the stock a “hold” rating in a research report on Wednesday, August 5th. Royal Bank Of Canada raised their price objective on shares of Bio-Rad Laboratories from $320.00 to $370.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 5th. Weiss Ratings upgraded Bio-Rad Laboratories from a “sell (d)” rating to a “hold (c-)” rating in a research report on Monday, August 17th. Finally, Wells Fargo & Company upped their target price on Bio-Rad Laboratories from $310.00 to $330.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 5th. One equities research analyst has rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $343.33.

Bio-Rad Laboratories Price Performance

Shares of NYSE BIO opened at $390.10 on Wednesday. The company has a current ratio of 3.14, a quick ratio of 2.33 and a debt-to-equity ratio of 0.11. The company’s 50-day moving average price is $319.88 and its 200 day moving average price is $293.95. Bio-Rad Laboratories has a 52 week low of $236.73 and a 52 week high of $390.83. The stock has a market cap of $10.43 billion, a price-to-earnings ratio of 47.28 and a beta of 1.06.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings results on Tuesday, August 4th. The medical research company reported $2.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.75 by $0.87. Bio-Rad Laboratories had a return on equity of 3.54% and a net margin of 8.59%.The business had revenue of $651.00 million during the quarter, compared to the consensus estimate of $623.99 million. During the same quarter in the previous year, the company posted $2.61 EPS. The business’s revenue was down .1% on a year-over-year basis.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. California State Teachers Retirement System boosted its stake in shares of Bio-Rad Laboratories by 27,700.0% during the 2nd quarter. California State Teachers Retirement System now owns 6,097,105 shares of the medical research company’s stock worth $1,790,171,000 after purchasing an additional 6,075,173 shares during the last quarter. First Eagle Investment Management LLC raised its position in shares of Bio-Rad Laboratories by 2.0% in the fourth quarter. First Eagle Investment Management LLC now owns 2,570,473 shares of the medical research company’s stock valued at $778,828,000 after buying an additional 50,154 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Bio-Rad Laboratories by 1.1% in the first quarter. Dimensional Fund Advisors LP now owns 1,089,323 shares of the medical research company’s stock valued at $303,637,000 after buying an additional 12,251 shares during the last quarter. Capital Research Global Investors boosted its position in Bio-Rad Laboratories by 18.2% during the fourth quarter. Capital Research Global Investors now owns 494,472 shares of the medical research company’s stock worth $149,820,000 after acquiring an additional 76,117 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in Bio-Rad Laboratories by 1.7% in the 3rd quarter. Bank of America Corp DE now owns 459,887 shares of the medical research company’s stock worth $128,948,000 after acquiring an additional 7,754 shares during the period. 65.24% of the stock is currently owned by hedge funds and other institutional investors.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.